Eton Pharmaceuticals Beats Q3 2026 Estimates as Revenue Rises 158% to $57.9M

Eton Pharmaceuticals (ETON) beat estimates for the third quarter of 2026 on both revenue and adjusted EPS. Revenue was $57.9 million, up 158% from a year earlier, above the $42.0 million estimate, and adjusted EPS was $0.50 above the $0.31 estimate.

Shares were unchanged in after-hours trading as of 4:04 p.m. ET, to $47.15 from a $47.15 close.

Q3 2026 scorecard

By our calculation, revenue was $15.9 million above the estimate and adjusted EPS was $0.19 above it. The QoQ column compares with the previous quarter's revenue of $37.6 million and adjusted EPS of $0.35. The YoY column compares with $22.5 million and -$0.07 in the same quarter a year earlier.

Track record

• EPS record. Adjusted EPS beat the estimate in 2 of the last 8 reports, including this one.
• Revenue record. Revenue beat the estimate in 6 of the last 8 reports.
• Revenue trend. Revenue over the last 5 reports, oldest first: $22.5 million, $21.3 million, $24.3 million, $37.6 million and $57.9 million.

What to watch

• Next-quarter estimates. Consensus calls for EPS of $0.37 and revenue of $45.9 million next quarter, based on 2 analysts.
• Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 158% increase to $57.9 million.
• Estimate record. Whether Eton Pharmaceuticals returns to beating EPS estimates, which it did in 2 of its last 8 reports.
• Related coverage. See our reports on BlackLine, BJ's Restaurants, Federal Agricultural Mortgage and AvePoint.

Sources: Results are from Eton Pharmaceuticals's Nov. 5, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Eton Pharmaceuticals's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.